Chronotherapeutic Considerations in Immunotherapy: A Case of Durable Response in Metastatic Non-small Cell Lung Cancer

Jun 19, 2026Prague medical report

Timing treatment to the body’s daily rhythms may support long-lasting immune therapy response in advanced lung cancer

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

A patient with metastatic non-small cell lung cancer achieved a lasting full response to pembrolizumab for more than 6 years.

Consistent morning administration of immune checkpoint inhibitors may correlate with improved long-term responses.
The neutrophil-to-lymphocyte ratio (NLR) remained stable between 2.16 and 3.66 throughout the treatment period.
Stable NLR levels could indicate enhanced immune function aligned with early-day immune activity.
Circadian patterns may influence the effectiveness of immunotherapy, particularly in activating innate immune cells.
The variability in timing of immunotherapy treatments in current medical practice may impact overall efficacy.

AI simplified

Chronotherapy, the alignment of treatments with biological rhythms, has been explored in oncology, particularly for chemotherapy and targeted therapies, but its impact on immune checkpoint inhibitor (ICI) efficacy remains underexplored. This research aimed to examine the potential chronotherapeutic effects of morning ICI administration on the long-term response to pembrolizumab in metastatic non-small cell lung cancer (NSCLC), emphasising immune function stability via the neutrophil-to-lymphocyte ratio (NLR), and to assess the clinical significance of circadian synchronisation in immunotherapy. This study utilised a retrospective case study methodology, examining the treatment records and serial hematologic data of a patient with metastatic NSCLC. A patient diagnosed with metastatic NSCLC in 2019 showed a lasting full response to pembrolizumab for more than 6 years. A retrospective analysis revealed consistent morning ICI administration (08:00-11:00 h) and a stable NLR (2.16-3.66) during the treatment period. In addition, serial haematologic analysis showed a stable NLR, ranging between 2.16 and 3.66 throughout the treatment course. This immunological stability may reflect enhanced immune function aligned with early-day innate immune activity, particularly neutrophil and antigen-presenting cell priming, which is known to follow circadian patterns. Although specific molecular circadian markers were not examined, this case highlights a significant issue in current medical practice: there is almost no consistency in the timing of immunotherapy treatments. Taken together with emerging retrospective data, these findings underscore the need for prospective studies evaluating the influence of treatment timing on immunotherapy efficacy and durable immune surveillance in solid tumours.

Full Text

Full text is available at the source.

View full text (PDF) ↗

Chronotherapeutic Considerations in Immunotherapy: A Case of Durable Response in Metastatic Non-small Cell Lung Cancer

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief